Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenetic-guided warfarin dosing after rheumatic valve replacement
ChiCTR-TRC-11001852Phase 4Completed
- Sponsor
- Tongji Hospital
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of warfarin in rheumatic heart disease (RHD) and Cardiac valve disease (VHD) (2 arms), sponsored by Tongji Hospital. Primary endpoints: Warfarin maintenance dose, International normalized ratio and 1 more. Started Jan 2010; status: completed.
02
Drugs
warfarin
03
Conditions
rheumatic heart disease (RHD)Cardiac valve disease (VHD)
Beyond the preview
Go deeper on ChiCTR-TRC-11001852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11001852.